Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Fulcrum Therapeutics, Inc.

35 indications, side-by-side phase, drug & LoA

$3.45

-0.1 (-2.82%)

D 38Pipeline Score Fair Value Pharma · Commercial
Market Cap
437.78 M
EPS
-1.15
P/E Ratio
-
Value Trade
17.82 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • R&D Expenses

    14.08 M

  • Operating CF

    -18.75 M

  • Total Assets

    346.77 M

  • Total Liabilities

    13.47 M

  • Equity

    333.30 M

  • D/E Ratio

    12,345

-5.87 %
Week
-13.32 %
1 Month
-43.31 %
3 Month
-40.27 %
6 Month
-34.43 %
5 Year
-54.69 %
All Time
Cash Data
Healthy

  • Cash Position

    333.32 M

  • Monthly Burn

    6.25 M

  • Runway

    51.9 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    Apr 27, 2026
Overview
Volume
1.34 M
52 Week Range
5.88 - 15.74
% held by Insiders
15.33 %
% held by Institutions
93.67 %
Enterprise Value
110.33 M
Total Shares
66.64 M
Short %
13.01 %
Float Shares
61.44 M
Company Description
HQ: 26 LANDSDOWNE STREET, CAMBRIDG...
Employees:55
https://www.fulcrumtx.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 1b data readout example
pociredir sickle cell disease
Phase 1b
—
Small Molecules
Hematologic System
pociredir sickle cell disease
Phase 1b
—
Small Molecules
Hematologic System
pociredir sickle cell disease
Phase 1b
—
Small Molecules
Hematologic System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D38
Pipeline Score
$416M
Pipeline Value
Fair Value
Valuation Signal
3
Drugs Scored
1.0x
rNPV / MCap
Top 48%
Micro Cap
(rank 472 of 905)
Percentile Rank
Fulcrum Therapeutics, Inc. faces pipeline headwinds (38/100), with $1.0B risk-adjusted pipeline value, led by Pociredir in Sickle Cell Disease (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Pociredir
Small molecule		Sickle Cell DiseasePhase 2NCT0516958060% $521M COMPLETED 119 - -Jan 20, 2026ELEVATED_RISKFeb 12, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
pociredir
sickle cell disease
Phase 1b
2025-07-29
pociredir
sickle cell disease
Phase 1b
2025-07-29
pociredir
sickle cell disease
Phase 1b
2025-07-29
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in FULC
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
FULC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
FULC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
FULC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
FULC Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
FULC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Fulcrum Therapeutics, Inc. (FULC) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How FULC ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Sickle Cell Disease #7 of 12 PHASE 2 Pociredir
NVO NVS SNY
$4.23B 0.86 FOLLOWER